On 8 July 2022, Rainmed Medical Limited (2297.HK) successfully made its initial public offering and was listed on the Mainboard of Hong Kong Stock Exchange with a market value of HKD 7,285 million at the time of listing based upon the issue price (regardless of over-allotment option).

Rainmed Medical is a company focusing on the design, development and commercialization of coronary angiography-derived fractional flow reserve (caFFR) systems and coronary angiography-derived index of microcirculatory resistance (caIMR) systems. 

Grandall Shanghai Office has been retained as the Chinese legal counsel of the underwriter and sponsor for this project with LI Peng, YUE Yongping, and ZHANG Qiang as key lawyers serving the case.